Inovio Pharmaceuticals (INO) Earnings Analysis
Inovio Pharmaceuticals (INO) next reports earnings on 2026-08-12, consensus EPS -0.25 USD. Last quarter (2026-03-12) it beat with EPS 0.31 USD vs -0.37 USD est (+183.8%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E -0.62.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does INO next report earnings?
| Next earnings date | 2026-08-12 |
|---|---|
| Consensus EPS estimate | -0.25 USD |
| Revenue estimate | 0.00B |
INO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-12 | 0.31 USD | -0.37 USD | +183.8% | Beat |
| 2025-11-10 | -0.44 USD | -0.51 USD | +13.7% | Beat |
| 2025-03-18 | -0.69 USD | -0.87 USD | +20.7% | Beat |
| 2024-11-14 | -0.89 USD | -1.2 USD | +25.8% | Beat |
| 2024-08-08 | -1.19 USD | -1.15 USD | -3.5% | Miss |
Beat rate: 4/5 (80%) over reported quarters with consensus data.
INO valuation and analyst view
| Trailing P/E | -0.62 |
|---|---|
| Trailing EPS | -0.12291 USD |
| Price / book | 120.71 |
| Dividend yield | 0.00% |
| Market cap | 0.06B |
| Analyst consensus | Buy (9 buy / 6 hold / 2 sell) |
| Avg price target | 2.5 USD |
Related research pages
Frequently asked questions
When is Inovio Pharmaceuticals (INO)'s next earnings date?
Inovio Pharmaceuticals is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.25 USD and revenue estimate of 0.00B.
Did INO beat earnings last quarter?
In its 2026-03-12 report, INO posted EPS of 0.31 USD versus a -0.37 USD estimate — a beat of 183.8%.
What is INO's earnings track record?
Over the last 5 reported quarters with consensus data, INO beat estimates 4 times (80%).
What is INO's current P/E ratio and EPS?
INO trades at a trailing P/E of -0.62 on trailing EPS of -0.12291123977777746 USD.
What do analysts rate INO?
Analyst consensus is "Buy" across 17 ratings (0 strong buy, 9 buy, 6 hold, 2 sell, 0 strong sell). Average 12-month price target: 2.5 USD.